Ionis Pharmaceuticals Inc (IONS)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$76.48
Buy
$76.59
$0.48 (+0.63%)
Prices updated at 08 May 2026, 16:11 EDT
| Prices minimum 15 mins delay
Prices in USD
Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Joseph Loscalzo, M.D.,PhD
CEO
Dr. Brett P. Monia, PhD
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
1,402
Head office
2855 Gazelle Court
Carlsbad
United States
92010
Key personnel
Owner name | Salary |
|---|---|
Ms. B. Lynne Parshall, Esq.,J.D. Director | 0.09m |
Mr. Joseph H. Wender Lead Independent Director | 0.15m |
Mr. Peter N. Reikes Director | - |
Mr. Joseph Klein, III Independent Director | 0.10m |
Dr. Joseph Loscalzo, M.D.,PhD Chairman of the Board | 0.12m |
Dr. C. Frank Bennett,PhD Executive Vice President and Chief Scientific Officer | - |
Ms. Joan E. Herman Independent Director | 0.09m |
Dr. Spencer R. Berthelsen,M.D. Independent Director | 0.10m |
Dr. Michael Hayden, M.D.,PhD Independent Director | 0.08m |
Dr. Brett P. Monia, PhD Chief Executive Officer and Director | 1.05m |
Ms. Elizabeth L. Hougen Executive Vice President, Finance, Principal Accounting Officer and Chief Financial Officer | 0.73m |
Mr. Patrick R. O'Neil, Esq. Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary | 0.61m |
Mr. Michael J. Yang Independent Director | 0.07m |
Ms. Allene M. Diaz Independent Director | 0.08m |
Mr. Kyle Jenne Executive Vice President and Chief Global Product Strategy Officer | - |
Mr. Eric E. Swayze, PhD Executive Vice President, Research | 0.59m |
Mr. Joseph T. Baroldi Executive Vice President and Chief Business Officer | - |
Mr. Eugene Schneider Executive Vice President and Chief Clinical Development and Operations Officer | - |
Mr. Brian Birchler Executive Vice President, Corporate and Development Operations | 0.58m |
Ms. Shannon L. Devers Executive Vice President and Chief Human Resources Officer | - |
Dr. Holly B. Kordasiewicz, PhD Executive Vice President and Chief Development Officer | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| FMR Inc | 24,072,101 |
| Fidelity Management and Research Company | 24,072,101 |
| Capital Research and Management Company | 21,080,087 |
| Capital World Investors | 17,961,299 |
| Vanguard Group Inc | 16,440,459 |
Director dealings
Date | Action |
|---|---|
| 01 Dec 2025 | - |
| 01 Dec 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 25 Nov 2025 | - |
| 19 Nov 2025 | - |
| 19 Nov 2025 | - |
| 19 Nov 2025 | - |
| 19 Nov 2025 | - |
| 19 Nov 2025 | - |
| 19 Nov 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
